- Vremaining isite (at 3 months) carried out for thethe final sufferers September 16
- 691 sufferers recruited within the Mont Blanc examine
- Fundamental outcomes of the Mont Blanc examine anticipated starting November 2022
September 19, 2022 – broadcast at 7:30 a.m.
Nicox S.A. (Euronext Paris: FR0013018124, COX, PEA-PME eligible), a world firm specializing in ophthalmology, declares right now that the final go to (at 3 months) was carried out by the final sufferers of the Mont Blanc part 3 scientific examine on NCX 470 0.1% for discount of intraocular stress (IOP) in sufferers with open-angle glaucoma or ocular hypertension. A complete of 691 sufferers have been recruited into the examine. NCX 470, Nicox’s lead drug candidate in scientific improvement, is a novel, probably best-in-class nitric oxide (NO)-donating prostaglandin analog eye drop.
“We’re blissful to have taken this step.yr the scientific examine of pbase 3 Mont Blanc, and I want to thank significantly our scientific websites and the Nicox improvement crew for his or her excellent efforts with a view to perform this examine in context of the pandemic of COVID-19.” mentioned Doug Hubatsch, EVP, Chief Scientific Officer of Nicox. “NCX470 has the potential to change into the very best at school remedy for the glaucoma and we look ahead to to current the principle outcomes of the examine to starting of the month of november.”
The Mont Blanc examine is a world, double-blind, 3-month, parallel-group examine to evaluate the efficacy and security of NCX 470 ophthalmic resolution 0.1% compared to latanoprost ophthalmic resolution 0.005%. Latanoprost is probably the most extensively prescribed first-line remedy for open-angle glaucoma or ocular hypertension. The first efficacy evaluation within the Mont Blanc examine relies on IOP on the 8:00 a.m. and 4:00 p.m. evaluation instances on the 2th week, the 6th week and on the threeth month.
Denali’s second Section 3 examine of NCX 470 is being collectively carried out and equally funded with Nicox’s accomplice, Ocumension Therapeutics. The principle outcomes of the examine are presently anticipated after 2024.
Nicox SA is a world firm specializing in ophthalmology growing progressive options geared toward sustaining imaginative and prescient and bettering eye well being. Nicox’s lead program in scientific improvement is NCX 470, a novel nitric oxide-donating prostaglandin analog for the discount of intraocular stress in sufferers with glaucoma or ocular hypertension. The Firm can also be conducting analysis on NCX 1728, an inhibitor of NO-donating phosphodiesterase 5, within the discount of intraocular stress and in illnesses of the retina. NCX 4251, an progressive, patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular utility for dry eye, is being developed by Ocumension Therapeutics in China beneath an unique license settlement, and is on the market for partnership elsewhere. Nicox generates income from VYZULTA®licensed completely worldwide to Bausch + Lomb, in glaucoma, and ZERVIATE® in allergic conjunctivitis. ZERVIATE is licensed in a number of territories, together with Eyevance Prescription drugs, LLC, (a subsidiary owned by Santen Pharmaceutical Co., Ltd.) for the US and Ocumension Therapeutics for the Chinese language markets and nearly all of international locations in South Asia. South East.
Nicox, whose head workplace is in Sophia Antipolis (France), is listed on Euronext Paris (Compartment C: Mid Caps; Ticker: COX) and is a part of the CAC Healthcare, CAC Pharma & Bio and Subsequent 150 indices.
For extra data on Nicox, its merchandise or its portfolio: www.nicox.com
Edison Funding Analysis Pooya Hemami London, United Kingdom HC Wainwright & Co Yi Chen New York, United States Kepler Cheuvreux Arsene Guekam France, United States
Government Vice President, Chief Enterprise Officer
& Head of Company Growth
T +33 (0)4 97 24 53 00
Investor and Media Relations
USA & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
The danger elements more likely to have a big affect on Nicox SA’s enterprise are set out in Chapter 3 of the 2021 Common Registration Doc, Annual Report and Administration Report which was filed with the AMF on April 29, 2022. and which is on the market on the Nicox web site (www.nicox.com).
Constructing D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99